GlassScriptPhysician profile
Claude M Bridges
NPI 1619956000
$1,872.93
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $888 · 2022: $856.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.97 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $200.56 | 2021-2022 | |
| Janssen Biotech, INC. | $191.64 | 2021-2022 | |
| Esperion Therapeutics, INC. | $186.62 | 2021 | |
| Abbvie INC. | $160.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $121.08 | 2020-2022 | |
| Lilly USA, LLC | $97.68 | 2021-2022 | |
| Pfizer INC. | $93.06 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.21 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $47.81 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.34 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $45.65 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.92 | 2022 | |
| Amarin Pharma, INC. | $30.90 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.06 | 2021 | |
| Dynavax Technologies Corporation | $21.10 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.85 | 2020 | |
| Ucb, INC. | $19.08 | 2022 | |
| Nabriva Therapeutics, Plc | $18.22 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.92 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.28 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.